Valuation : HitGen Inc.

Market Cap 12.97B 1.93B 1.66B 1.57B 1.43B 2.67B 182B 2.69B 18.57B 7.21B 93.21B 7.25B 7.09B 306B P/E 2026 *
93.2x
P/E 2027 * 72.3x
Enterprise Value 12.97B 1.93B 1.66B 1.57B 1.43B 2.67B 182B 2.69B 18.57B 7.21B 93.21B 7.25B 7.09B 306B EV / Sales 2026 *
20x
EV / Sales 2027 * 16.2x
Free-Float
50.43%
Yield 2026 *
0.28%
Yield 2027 * 0.46%
1 day-0.19%
1 week-7.33%
Current month+0.40%
1 month+17.24%
3 months+18.10%
6 months+10.55%
Current year+38.04%
1 week 30.9
Extreme 30.9
35.34
1 month 26.18
Extreme 26.18
41.78
Current year 22.42
Extreme 22.42
42.98
1 year 21.46
Extreme 21.46
42.98
3 years 8.35
Extreme 8.35
42.98
5 years 8.35
Extreme 8.35
42.98
10 years 8.35
Extreme 8.35
61.99
Manager TitleAgeSince
Chief Executive Officer 63 2012-05-31
Director of Finance/CFO 56 2023-04-26
Investor Relations Contact 38 2019-06-30
Director TitleAgeSince
Chairman 63 2012-05-31
Director/Board Member 63 -
Director/Board Member 65 2019-03-23
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-7.33%+20.16%+115.66% 1.93B
+1.03%-3.11%+39.80%+94.60% 68.21B
+1.62%+2.43%+48.66%+88.33% 64.25B
+4.21%+1.80%-12.85%+380.20% 26.54B
+1.83%-7.77%+3.17%-14.91% 25.61B
+1.30%-0.96%+32.58%-17.99% 19.88B
-0.38%-12.42%+224.86%+373.18% 17.13B
+0.65%-5.83%+1.44%+544.44% 14.93B
+2.88%+4.33%+57.42%+162.82% 14.1B
+1.53%+1.49%+25.41%+196.44% 12.45B
Average +1.45%-3.77%+44.07%+192.28% 26.5B
Weighted average by Cap. +1.59%-3.02%+42.52%+154.56%

Financials

2026 *2027 *
Net sales 647M 96.33M 83.11M 78.29M 71.33M 133M 9.1B 134M 927M 360M 4.65B 362M 354M 15.28B 802M 119M 103M 96.93M 88.31M 165M 11.27B 166M 1.15B 445M 5.76B 448M 438M 18.92B
Net income 140M 20.86M 18M 16.95M 15.45M 28.87M 1.97B 29.09M 201M 77.89M 1.01B 78.33M 76.62M 3.31B 179M 26.62M 22.96M 21.63M 19.71M 36.84M 2.51B 37.11M 256M 99.38M 1.29B 99.94M 97.76M 4.22B
Net Debt - -
Logo HitGen Inc.
HitGen Inc is a China-based company primarily engaged in the research, development and optimization of small molecule and nucleic acid-based new drug candidates using deoxyribonucleic acid (DNA) encoded chemical library (DEL) technology. Through the drug discovery and optimization platform, the Company provides clients with services such as screening and optimization of designated biological targets, customized DEL design and synthesis, synthesis and modification of certain designated compounds or nucleic acids and related biological evaluation. The Company is also engaged in the transfer of rights and interests in new drug research projects, capital operations and marketing activities. The Company primarily operates its businesses in the domestic market and overseas markets, including the United States, France, the United Kingdom and Japan.
Employees
546
Date Price Change Volume
26-09-01 CN¥32.37 -0.19% 16,871,670
26-09-01 CN¥32.43 +0.59% 13,979,236
26-08-31 CN¥32.24 -1.89% 16,937,422
26-08-28 CN¥32.86 -2.55% 16,350,367
26-08-27 CN¥33.72 -0.27% 18,893,289
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
32.37CNY
Average target price
42.20CNY
Spread / Average Target
+30.37%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 688222 Stock